<DOC>
	<DOCNO>NCT00477945</DOCNO>
	<brief_summary>This phase I trial determine maximum tolerate dose ( MTD ) clofarabine combination high-dose etoposide cyclophosphamide . This initial step develop novel myeloablative preparative regimen autologous hematopoietic stem cell transplantation ( ASCT ) . While phase I trial initially develop regimen patient refractory disease , expect find best application patient less advanced disease .</brief_summary>
	<brief_title>Phase I Trial Clofarabine Combo w/ HD Etoposide &amp; Cyclophosphamide APBSCT Pts w/ High-Risk Refractory NHL</brief_title>
	<detailed_description>All patient receive dos etoposide cyclophosphamide . The dose clofarabine escalate successive cohort patient . Using standard dose escalation design , successive cohort 3 patient treat escalate dos clofarabine ( see Section 5.5 ) . At MTD ( high dose-level MTD reach ) , cohort expand 10 patient well investigate correlative study give preliminary idea efficacy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>1 . Documentation disease . Patients must one follow disease type : Diffuse large cell nonHodgkin 's lymphoma , mediastinal Bcell lymphoma , peripheral Tcell lymphoma : Primary refractory ( achievement less complete response ) Relapsed refractory ( achievement less partial response ) least single salvage therapy Relapsed primary refractory Follicular lymphoma ( FL ) high FL International Prognostic Index . Large cell transformation lymphoma indolent lymphoma ( e.g. , follicular , marginal zone , etc . ) Mantle cell lymphoma : Primary Refractory ( achievement less complete response ) Relapsed ( regardless chemosensitivity relapse disease ) 2 . Patients receive prior autologous stem cell transplantation eligible . 3 . Patient age 1870 year 4 . Performance status ECOG 01 5 . Required baseline laboratory value : LVEF &gt; 45 % correct DLCO &gt; 50 % predict value ( correct hemoglobin ) Serum creatinine ≤ 2.0 mg/dl estimate creatinine clearance ≥60 ml/min Bilirubin &lt; 1 x upper limit normal value . AST ALT &lt; 1 x upper limit normal value . 6 . Signed write informed consent . Patient must capable understanding investigational nature investigational nature , potential risk benefit study , able provide valid inform consent 1 . No active infection . Patients active infection require oral intravenous antibiotic eligible enrollment resolution infection . 2 . No HIV disease . Patients immune dysfunction significantly high risk infection intensive immunosuppressive therapy . 3 . Nonpregnant nonnursing . Treatment protocol would expose fetus significant risk . Women childbearing potential negative pregnancy test prior study entry . Women men reproductive potential agree use appropriate method birth control throughout participation study due teratogenic potential therapy utilized trial . Appropriate method birth control include oral contraceptive , implantable hormonal contraceptive ( Norplant® ) , double barrier method ( diaphragm plus condom ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Non Hodgkin 's Lymphoma</keyword>
	<keyword>High Risk Refractory Non Hodgkin 's Lymphoma</keyword>
	<keyword>APBSCT</keyword>
	<keyword>clofarabine</keyword>
</DOC>